Corrigendum to Bent et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol (doi: 10.1093/neuonc/noz222) first published online November 20, 2019.
In table 2, the rows in the hematology and investigation sections were misplaced one line. This has been corrected.
